EXOZ

$EXOZ chatter on StockTwits

• 
  James@Slack_CapitalBullishJul 25

  $EXOZ @eXoZymes receives grant funding to build an AI model that predicts how its cell-free enzymatic pathways will perform under different conditions. The ambition is to computationally determine optimal cell-free parameters (temperature, pH, concentrations, enzyme ratios) and estimate performance outputs like synthesis yields, titres and rates. The team has already developed an AI model to optimise an enzyme's design in a cell-free environment... and this next step extends the company's capability to predict full pathway performance across process conditions. If the team can successfully design such a model, this would be a monumental breakthrough, further reducing eXoZymes' compound development timeframes and DBTL costs. Eventually, this could lead the company to develop and spin-out multiple high-value, IP-protected compounds every single year. https://exozymes.com/blog/genesis-mission-2026

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJul 24

  eXoZymes (Nasdaq: $EXOZ ) is among the first projects selected for the inaugural U.S. Department of Energy (DOE) Genesis Mission, a nationwide initiative bringing together national laboratories, universities, companies, and nonprofit organizations to accelerate scientific discovery. eXoZymes will work with Lawrence Berkeley National Laboratory to build AI-powered digital twins for its cell-free biomanufacturing platform. eXoZymes is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes The project extends the company’s AI work from enzyme engineering into manufacturing: • With Berkeley Lab, eXoZymes will develop hybrid digital twins that combine enzyme kinetics, reactor physics, and machine learning to identify optimal operating conditions before lab validation • The award provides access to the DOE Genesis Mission Platform: advanced AI models, AI agents, and high-performance computing • Subject to DOE award negotiations, the project is expected to carry about $747,000 in total funding, including about $147,000 for eXoZymes “We believe the next generation of biomanufacturing will be built at the intersection of artificial intelligence and digital insights into biology,” said Michael Heltzen, Chief Executive Officer of eXoZymes. Read the full release: https://exozymes.com/blog/genesis-mission-2026 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJul 23

  eXoZymes (Nasdaq: $EXOZ ) frames itself as a repeatable engine for unlocking molecule classes. In a Webull webinar, Chief Commercial Officer Damien Perriman put cannabinoids forward as the next class after NCT. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "This is not a single product company. It's a repeatable system for unlocking entire classes of molecules," Perryman told investors. Also from the presentation: • NCT is the first proof point and cannabinoids are the second, with cannabinoid receptors present on nearly every cell in the body • That reach spans metabolic, inflammatory, and neurological conditions, where access to rare cannabinoids has long been the bottleneck • eXoZymes says it can now produce rare and entirely new cannabinoids without intoxicating components, optimized toward specific therapeutic objectives Watch the full webinar: https://youtu.be/OmH3TaaMT20 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJul 17

  A platform that works in the lab is not yet a business. In a Webull webinar, eXoZymes (Nasdaq: $EXOZ ) pointed to a scale-up run it says clears that bar. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 Perryman framed the milestone directly: "Many technologies work in the lab, but many also fail at scale. What we've demonstrated here is that the system translates from concept to industrial conditions, and that's what turns this from a science into a viable business." The webinar detailed the run: • The company ran a 100-liter pilot at the end of last year, reporting 99% conversion of raw material to target product and 99.6% purity • The run took place at a third party after eXoZymes tech-transferred its process, operating conditions, and enzyme cascades • Management called this an operational process rather than a theoretical one, and an inflection point for investors Watch the full webinar: https://youtu.be/OmH3TaaMT20 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

  View on StockTwits ↗
• 
  Ivan@_ivanJul 16

  $ARKG $DNA $DNLI $EXOZ $TWST

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJul 14

  eXoZymes (Nasdaq: $EXOZ ) is targeting metabolic dysfunction a layer deeper than appetite. In a recent Webull webinar, Chief Commercial Officer Damien Perriman walked investors through NCT, the company's first proof point. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "It is fundamentally different from GLP-1 drugs," Perryman said. "GLP-1s reduce appetite, whereas NCT and its activation of HNF4 alpha improves mitochondrial biogenesis and mitochondrial activity, essentially improving how the body burns fat." From the same segment: • NCT activates HNF4 alpha, a master metabolic control switch, rather than acting on a single downstream symptom • In controlled preclinical models on identical diets, eXoZymes reported 30% to 40% less weight gain in the mouse population • The company also observed improved mitochondrial function and reduced liver fat, consistent with hitting a central regulatory pathway Watch the full webinar: https://youtu.be/OmH3TaaMT20 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJul 8

  eXoZymes (Nasdaq: $EXOZ ) makes its case for cell-free biomanufacturing, the approach it says sidesteps where whole-cell synthetic biology has repeatedly failed to scale. Whole-cell synthetic biology has a long record of stalling at scale. In a Webull webinar, eXoZymes Chief Commercial Officer Damien Perriman laid out why the company removed the cell from the equation entirely. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "Engineered cells have become a boulevard of broken dreams on Wall Street, and eXoZymes found a way to navigate around this problem," said Damien Perryman, Chief Commercial Officer of eXoZymes. In the webinar, Perryman also covered: • Cells evolved to survive, not to manufacture, so whole-cell systems carry biological noise, toxicity limits, and regulatory complexity into production • eXoZymes isolates the enzymes, engineers them with AI, and runs them outside the cell to produce target molecules cleanly and at scale • The result behaves more like precision chemistry than a biological production system, inspired by biology's own catalysts Watch the full webinar: youtube.com/watch?v=OmH3TaaMT20&feature=youtu.be eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

  View on StockTwits ↗
• 
  James@Slack_CapitalBullishJul 3

  $EXOZ Reminder that we've set up an eXoZymes discord group!

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJun 25

  eXoZymes (Nasdaq: $EXOZ) secures $2 million NIH grant, expanding its proprietary pharmaceutical biosolutions pipeline into non-intoxicating cannabinoids. Federal research funding extends eXoZymes’ cell-free platform further into drug discovery. eXoZymes Inc. (Nasdaq: EXOZ) has received a Notice of Award from the National Institutes of Health for a roughly $2 million Phase IIB SBIR grant to produce rare cannabinoids and engineer cannabinoid analogs for pharmaceutical evaluation. The award adds a second biosolution to the pipeline alongside NCT, expands the company’s portfolio of proprietary pharmaceutical assets, and lifts total non-dilutive funding awarded to eXoZymes and its predecessor programs to approximately $19.7 million. The two-year program begins July 1, 2026. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 Michael Heltzen, CEO of eXoZymes, commented: “This is a key milestone that demonstrates our repeatable development engine of future licensing and partnering opportunities - a key feature in creating additional proprietary molecules without diluting shareholders.” From the announcement: • The grant supports work to build cannabinoid cyclase expression systems, widen the analog range, and run preclinical receptor-binding evaluation of the cannabinoid library • It arrives as the US minor cannabinoids market is forecast to grow from $11.5 billion in 2023 to $33.3 billion by 2030 See the full release: https://exozymes.com/blog/grant-cannabinoid-analogs eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

  View on StockTwits ↗
• 
  PRISM MarketView@prismmarketviewJun 25

  $EXOZ got a new NIH Phase IIB SBIR grant worth ~$2.03M to support rare cannabinoid and cannabinoid‑analog programs, starting July 1, 2026. Total non‑dilutive funding now sits near $19.7M. #EXOZ #NIH #biotech #AI https://prismmarketview.com/nih-cash-fuels-exozymes-push-into-next-gen-cannabinoids/

  View on StockTwits ↗
• 
  Top Stock Alerts@topstockalertsJun 24

  eXoZymes shares rose in after-hours trading after the company announced it had received a $2.03 million NIH Phase IIB Small Business Innovation Research grant to advance its cannabinoid analog research program. The funding, which begins on July 1, 2026, will support the development of rare cannabinoids and engineered cannabinoid analogs using eXoZymes’ cell-free production platform. The grant includes approximately $1.03 million for the first budget period and $994,000 for the second year, subject to progress and funding availability. The program will focus on improving cannabinoid cyclase enzyme expression systems, expanding the range of cannabinoid analogs the company can produce, and conducting preclinical receptor-binding studies on its existing cannabinoid library. The award increases eXoZymes’ total non-dilutive funding to nearly $19.7 million. $EXOZ

  View on StockTwits ↗
• 
  Classi@ClassiTraderJun 24

  $EXOZ

  View on StockTwits ↗
• 
  Classi@ClassiTraderJun 24

  $EXOZ 👀

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJun 23

  eXoZymes (Nasdaq: $EXOZ ) Chief Commercial Officer Damien Perriman will present at Webull’s Biotech Sector webinar on June 25, alongside Envoy Medical and IN8bio. Damien Perriman, Chief Commercial Officer of eXoZymes Inc. (Nasdaq: EXOZ), will present at Webull’s Biotech Sector webinar on June 25 at 2:00 p.m. Eastern, part of the Webull Corporate Connect series that spotlights publicly traded biotech companies for investors. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 eXoZymes is a synthetic biology company that takes enzymes out of the living cell and runs them on their own to manufacture hard-to-make molecules for nutraceutical and pharmaceutical markets. The session gives investors a chance to hear directly from the company’s commercial leadership. • The webinar takes place June 25 at 2:00 p.m. Eastern, 11:00 a.m. Pacific, and registration is free with a Webull account • Perriman presents alongside Brent Lucas, Chief Executive Officer of Envoy Medical, and Will Ho, Chief Executive Officer and co-founder of IN8bio • Perriman leads commercial strategy at eXoZymes, whose cell-free platform uses AI-engineered enzymes to convert low-cost feedstocks into high-value compounds Register for the webinar: https://exozymes.com/blog/webulls-biotech-webinar-2026 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

  View on StockTwits ↗
• 
  James@Slack_CapitalBullishJun 23

  $EXOZ The best way to understand @eXoZymes capital allocation strategy is to look at companies like ARM Holdings. ARM dominates the semiconductor industry by owning microchip architecture and never engaging in physical fabrication. Instead, ARM licenses its intellectual property to giants like Apple and Qualcomm, who handle production at foundries like TSMC. By remaining asset-light and focused on core R&D, ARM captures a staggering 97% gross margin on licensing fees and recurring royalties on every chip shipped. @eXoZymes runs a similar playbook adapted for biomanufacturing. Operating strictly as an R&D engine, the company designs enzymatic "architecture" for its innovative cell-free platform. Their proprietary biocatalytic pathways convert basic feedstocks into high-value nutraceutical and pharmaceutical analog compounds.

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.